Sorafenib
- PDF / 141,242 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 11 Downloads / 144 Views
1
S
Erythema multiforme: 3 case reports Two men and one woman developed erythema multiforme during treatment with sorafenib [route not stated] for renal cell carcinoma (RCC) or hepatocellular carcinoma (HCC). A 61-year-old woman developed erythema on a finger, 9 days after starting sorafenib 400 mg/day for RCC; the erythema progressed to involve her whole body. Furthermore, a 78-year-old man developed whole-body erythema on day 9 of treatment with sorafenib 800 mg/day for metastatic RCC. Additionally, a 74-year-old man began receiving sorafenib 400 mg/day for HCC; 6 days later he developed erythema on his sole which spread to his whole body. All patients had thumb-sized or smaller oedematous erythemas affecting their trunk and limbs, and diffuse facial erythema which spared the periorbital and perioral regions. Both men also had hand-foot skin reactions. Erythema multiforme was diagnosed in all three patients. Sorafenib was discontinued. They received topical corticosteroids, and their lesions gradually disappeared. Author comment: "[W]e describe three cases with sorafenib-induced [erythema multiforme]." Namba M, et al. Sorafenib-induced erythema multiforme: Three cases. European Journal of Dermatology 21: 1015-1016, No. 6, Nov-Dec 2011. Available from: 803068708 URL: http://dx.doi.org/10.1684/ejd.2011.1535 - Japan
0114-9954/10/1395-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 31 Mar 2012 No. 1395
Data Loading...
